Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bone Density | 66 | 2024 | 3534 | 4.170 |
Why?
|
Vitamin D | 37 | 2024 | 3291 | 2.520 |
Why?
|
Osteoporosis, Postmenopausal | 20 | 2024 | 393 | 2.470 |
Why?
|
Fractures, Bone | 24 | 2024 | 2041 | 2.460 |
Why?
|
Osteoporosis | 27 | 2023 | 1600 | 2.420 |
Why?
|
Cholecalciferol | 10 | 2024 | 550 | 2.270 |
Why?
|
Fatty Acids, Omega-3 | 9 | 2023 | 1387 | 2.090 |
Why?
|
Osteoporotic Fractures | 13 | 2024 | 409 | 2.060 |
Why?
|
Bone Density Conservation Agents | 10 | 2022 | 796 | 1.640 |
Why?
|
Body Composition | 17 | 2021 | 2419 | 1.570 |
Why?
|
Vitamin D Deficiency | 11 | 2023 | 1379 | 1.520 |
Why?
|
Hip Fractures | 18 | 2022 | 989 | 1.490 |
Why?
|
Dietary Supplements | 23 | 2024 | 3392 | 1.470 |
Why?
|
Absorptiometry, Photon | 32 | 2021 | 1736 | 1.410 |
Why?
|
Women's Health | 22 | 2024 | 2056 | 1.410 |
Why?
|
Postmenopause | 31 | 2024 | 2509 | 1.340 |
Why?
|
Accidental Falls | 6 | 2023 | 1056 | 1.180 |
Why?
|
Femur Neck | 11 | 2020 | 312 | 1.070 |
Why?
|
Cacao | 2 | 2023 | 98 | 0.970 |
Why?
|
Diet, Reducing | 6 | 2019 | 488 | 0.860 |
Why?
|
Dehydroepiandrosterone | 7 | 2016 | 257 | 0.850 |
Why?
|
Alendronate | 2 | 2020 | 173 | 0.750 |
Why?
|
Vitamins | 13 | 2023 | 1634 | 0.750 |
Why?
|
Bone and Bones | 9 | 2024 | 2560 | 0.700 |
Why?
|
Wrist Injuries | 2 | 2024 | 214 | 0.620 |
Why?
|
Parathyroid Hormone | 23 | 2023 | 1797 | 0.620 |
Why?
|
Calcium | 27 | 2023 | 5725 | 0.610 |
Why?
|
Overweight | 7 | 2023 | 2421 | 0.600 |
Why?
|
Osteoarthritis, Hip | 4 | 2011 | 406 | 0.540 |
Why?
|
Aged | 89 | 2024 | 169152 | 0.500 |
Why?
|
Weight Loss | 7 | 2023 | 2686 | 0.500 |
Why?
|
Double-Blind Method | 18 | 2023 | 12427 | 0.500 |
Why?
|
Spine | 6 | 2017 | 1111 | 0.490 |
Why?
|
Mesenchymal Stem Cells | 6 | 2020 | 1634 | 0.490 |
Why?
|
Femur | 12 | 2018 | 1302 | 0.480 |
Why?
|
Ulna Fractures | 1 | 2015 | 126 | 0.460 |
Why?
|
Minerals | 4 | 2011 | 283 | 0.450 |
Why?
|
Women | 1 | 2015 | 225 | 0.450 |
Why?
|
Anorexia Nervosa | 6 | 2014 | 1361 | 0.450 |
Why?
|
Estrogens | 5 | 2024 | 1520 | 0.440 |
Why?
|
Primary Ovarian Insufficiency | 2 | 2011 | 105 | 0.430 |
Why?
|
Bone Remodeling | 4 | 2018 | 580 | 0.430 |
Why?
|
Middle Aged | 96 | 2024 | 220352 | 0.430 |
Why?
|
Dehydroepiandrosterone Sulfate | 4 | 2006 | 240 | 0.430 |
Why?
|
Female | 129 | 2024 | 391270 | 0.430 |
Why?
|
Estrogens, Conjugated (USP) | 5 | 2024 | 275 | 0.380 |
Why?
|
Bone Resorption | 6 | 2014 | 720 | 0.380 |
Why?
|
Radius Fractures | 2 | 2024 | 513 | 0.370 |
Why?
|
Femoral Neck Fractures | 1 | 2012 | 141 | 0.360 |
Why?
|
Bone Diseases, Metabolic | 2 | 2017 | 409 | 0.360 |
Why?
|
Obesity | 12 | 2023 | 12922 | 0.350 |
Why?
|
Humans | 161 | 2024 | 760621 | 0.350 |
Why?
|
Osteoblasts | 6 | 2020 | 1142 | 0.350 |
Why?
|
Calcium, Dietary | 6 | 2017 | 531 | 0.350 |
Why?
|
Estrogen Replacement Therapy | 9 | 2024 | 1206 | 0.340 |
Why?
|
Weight Gain | 3 | 2023 | 2347 | 0.330 |
Why?
|
Osteogenesis | 5 | 2020 | 1271 | 0.320 |
Why?
|
Parathyroid Glands | 12 | 1990 | 517 | 0.320 |
Why?
|
Hyperhomocysteinemia | 1 | 2009 | 118 | 0.310 |
Why?
|
Radius | 1 | 2011 | 440 | 0.310 |
Why?
|
Aging | 10 | 2018 | 8651 | 0.290 |
Why?
|
Insulin-Like Growth Factor I | 6 | 2016 | 1928 | 0.280 |
Why?
|
Exercise | 7 | 2024 | 5787 | 0.270 |
Why?
|
Celiac Disease | 2 | 2013 | 822 | 0.270 |
Why?
|
Diphosphonates | 5 | 2022 | 638 | 0.260 |
Why?
|
Diet, Fat-Restricted | 2 | 2024 | 330 | 0.260 |
Why?
|
Homocysteine | 1 | 2009 | 640 | 0.260 |
Why?
|
Bone Marrow Cells | 7 | 2019 | 2414 | 0.250 |
Why?
|
Tibia | 1 | 2011 | 1065 | 0.250 |
Why?
|
Dietary Fats | 5 | 2019 | 1992 | 0.240 |
Why?
|
Breast Neoplasms | 10 | 2024 | 21025 | 0.240 |
Why?
|
Osteocalcin | 5 | 2002 | 274 | 0.240 |
Why?
|
Dietary Proteins | 3 | 2017 | 949 | 0.240 |
Why?
|
Risk Factors | 31 | 2023 | 74359 | 0.230 |
Why?
|
Adiposity | 4 | 2021 | 1858 | 0.230 |
Why?
|
Prednisone | 3 | 1995 | 1565 | 0.230 |
Why?
|
Male | 55 | 2024 | 359744 | 0.220 |
Why?
|
Drug Therapy | 1 | 2006 | 504 | 0.220 |
Why?
|
Alkaline Phosphatase | 5 | 2012 | 865 | 0.220 |
Why?
|
Ergocalciferols | 1 | 2024 | 110 | 0.220 |
Why?
|
Etidronic Acid | 1 | 2003 | 63 | 0.210 |
Why?
|
Incidence | 10 | 2024 | 21392 | 0.210 |
Why?
|
Premenopause | 5 | 2011 | 1038 | 0.210 |
Why?
|
RANK Ligand | 3 | 2014 | 318 | 0.200 |
Why?
|
Plant Extracts | 2 | 2023 | 496 | 0.200 |
Why?
|
Survivors | 4 | 2016 | 2375 | 0.200 |
Why?
|
Stromal Cells | 4 | 2019 | 1326 | 0.200 |
Why?
|
Calcifediol | 3 | 2012 | 161 | 0.200 |
Why?
|
Lower Extremity | 2 | 2017 | 1194 | 0.190 |
Why?
|
Adult | 51 | 2023 | 219994 | 0.190 |
Why?
|
Medroxyprogesterone Acetate | 4 | 2023 | 155 | 0.190 |
Why?
|
Triamcinolone Acetonide | 1 | 2001 | 100 | 0.190 |
Why?
|
Fatty Acids, Volatile | 1 | 2021 | 100 | 0.180 |
Why?
|
Aged, 80 and over | 21 | 2024 | 58995 | 0.180 |
Why?
|
Progestins | 2 | 2012 | 302 | 0.180 |
Why?
|
Follow-Up Studies | 11 | 2024 | 39261 | 0.180 |
Why?
|
Arthroplasty, Replacement, Hip | 3 | 2013 | 1406 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2024 | 10344 | 0.170 |
Why?
|
Forearm | 3 | 2020 | 429 | 0.170 |
Why?
|
Estradiol | 4 | 2017 | 1932 | 0.170 |
Why?
|
Men's Health | 1 | 2020 | 70 | 0.170 |
Why?
|
Kidney Failure, Chronic | 3 | 2009 | 2471 | 0.170 |
Why?
|
Survival | 1 | 2020 | 161 | 0.170 |
Why?
|
Body Mass Index | 11 | 2023 | 12914 | 0.170 |
Why?
|
Lumbar Vertebrae | 6 | 2017 | 1868 | 0.170 |
Why?
|
Tamoxifen | 2 | 2016 | 963 | 0.170 |
Why?
|
Glucocorticoids | 2 | 2001 | 2145 | 0.160 |
Why?
|
Menstrual Cycle | 2 | 2002 | 536 | 0.160 |
Why?
|
Monitoring, Physiologic | 1 | 2007 | 1784 | 0.160 |
Why?
|
Whole Body Imaging | 1 | 2021 | 278 | 0.160 |
Why?
|
Glomerular Filtration Rate | 3 | 2024 | 2180 | 0.160 |
Why?
|
Leiomyoma | 2 | 1994 | 654 | 0.160 |
Why?
|
Tea | 1 | 2020 | 284 | 0.150 |
Why?
|
Case-Control Studies | 12 | 2024 | 22053 | 0.150 |
Why?
|
Osteoprotegerin | 3 | 2014 | 177 | 0.150 |
Why?
|
Methylamines | 1 | 2019 | 138 | 0.150 |
Why?
|
Intra-Abdominal Fat | 2 | 2021 | 608 | 0.150 |
Why?
|
Cohort Studies | 11 | 2023 | 41335 | 0.150 |
Why?
|
Amenorrhea | 1 | 2001 | 480 | 0.150 |
Why?
|
Dietary Carbohydrates | 2 | 2013 | 892 | 0.150 |
Why?
|
Osteomalacia | 2 | 2002 | 56 | 0.140 |
Why?
|
Dietary Fiber | 1 | 2021 | 760 | 0.140 |
Why?
|
Spinal Fractures | 3 | 2017 | 702 | 0.140 |
Why?
|
Calcium Carbonate | 1 | 2016 | 62 | 0.140 |
Why?
|
Prospective Studies | 18 | 2024 | 54303 | 0.140 |
Why?
|
Hip Joint | 3 | 2015 | 1006 | 0.130 |
Why?
|
Waist Circumference | 3 | 2015 | 926 | 0.130 |
Why?
|
Foundations | 1 | 2016 | 97 | 0.130 |
Why?
|
Contraceptives, Oral, Combined | 2 | 2014 | 116 | 0.130 |
Why?
|
Hostility | 1 | 2016 | 183 | 0.130 |
Why?
|
Antineoplastic Agents | 3 | 2011 | 13630 | 0.130 |
Why?
|
Leuprolide | 2 | 1994 | 315 | 0.130 |
Why?
|
Coffee | 1 | 2020 | 582 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 3 | 2017 | 20509 | 0.130 |
Why?
|
Plant Proteins | 1 | 2018 | 370 | 0.130 |
Why?
|
gamma-Tocopherol | 1 | 2015 | 30 | 0.130 |
Why?
|
Menopause | 4 | 2023 | 1640 | 0.130 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2016 | 169 | 0.130 |
Why?
|
Cardiovascular Diseases | 5 | 2023 | 15757 | 0.130 |
Why?
|
Primary Prevention | 2 | 2020 | 1207 | 0.130 |
Why?
|
Netherlands | 1 | 2020 | 2213 | 0.120 |
Why?
|
Group Processes | 1 | 2016 | 226 | 0.120 |
Why?
|
Spondylitis, Ankylosing | 1 | 1996 | 152 | 0.120 |
Why?
|
Uterine Neoplasms | 2 | 1994 | 1439 | 0.120 |
Why?
|
Confidence Intervals | 3 | 2016 | 2932 | 0.120 |
Why?
|
Cell Differentiation | 7 | 2020 | 11481 | 0.120 |
Why?
|
Gastrointestinal Diseases | 1 | 2003 | 1190 | 0.120 |
Why?
|
Radioimmunoassay | 3 | 2007 | 866 | 0.110 |
Why?
|
Fibroblast Growth Factors | 1 | 2020 | 869 | 0.110 |
Why?
|
beta Carotene | 1 | 2015 | 524 | 0.110 |
Why?
|
Interleukin-6 | 2 | 2001 | 3215 | 0.110 |
Why?
|
Receptor, IGF Type 1 | 1 | 2016 | 380 | 0.110 |
Why?
|
Food Preferences | 1 | 2017 | 399 | 0.110 |
Why?
|
Hormone Replacement Therapy | 3 | 2014 | 755 | 0.110 |
Why?
|
Osteoclasts | 2 | 2014 | 711 | 0.110 |
Why?
|
Antioxidants | 2 | 2015 | 1667 | 0.110 |
Why?
|
Fractures, Spontaneous | 2 | 2008 | 231 | 0.110 |
Why?
|
United States | 13 | 2024 | 72461 | 0.100 |
Why?
|
Calcitonin | 2 | 2006 | 330 | 0.100 |
Why?
|
Collagen Type I | 3 | 2018 | 616 | 0.100 |
Why?
|
Baltimore | 1 | 2013 | 230 | 0.100 |
Why?
|
Life Style | 2 | 2024 | 3896 | 0.100 |
Why?
|
Sarcopenia | 1 | 2017 | 372 | 0.100 |
Why?
|
Hypocalcemia | 2 | 1991 | 199 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 11712 | 0.100 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2020 | 2290 | 0.100 |
Why?
|
Sodium, Dietary | 1 | 2016 | 425 | 0.100 |
Why?
|
Neoplasms | 4 | 2023 | 22072 | 0.100 |
Why?
|
Aromatase Inhibitors | 1 | 2016 | 511 | 0.100 |
Why?
|
Obesity, Abdominal | 1 | 2015 | 374 | 0.100 |
Why?
|
Calcification, Physiologic | 1 | 2012 | 170 | 0.100 |
Why?
|
Smoking | 5 | 2023 | 9073 | 0.100 |
Why?
|
Transglutaminases | 1 | 2013 | 197 | 0.100 |
Why?
|
Leptin | 1 | 2019 | 1591 | 0.100 |
Why?
|
Activities of Daily Living | 2 | 2023 | 2417 | 0.100 |
Why?
|
Sex Factors | 4 | 2020 | 10547 | 0.100 |
Why?
|
Adipose Tissue | 5 | 2021 | 3301 | 0.100 |
Why?
|
Tensile Strength | 1 | 2012 | 330 | 0.090 |
Why?
|
Radiography | 4 | 2017 | 6965 | 0.090 |
Why?
|
Guanylyl Imidodiphosphate | 1 | 1990 | 37 | 0.090 |
Why?
|
Biomedical Research | 2 | 2020 | 3426 | 0.090 |
Why?
|
Hand Strength | 2 | 2017 | 452 | 0.090 |
Why?
|
Self Report | 3 | 2017 | 3711 | 0.090 |
Why?
|
Societies, Scientific | 1 | 2011 | 221 | 0.090 |
Why?
|
Body Height | 1 | 2016 | 1570 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2011 | 3529 | 0.090 |
Why?
|
GTP-Binding Proteins | 4 | 2013 | 951 | 0.090 |
Why?
|
Cyclosporine | 1 | 1992 | 777 | 0.080 |
Why?
|
Biological Availability | 2 | 2018 | 395 | 0.080 |
Why?
|
Renal Insufficiency | 1 | 1995 | 820 | 0.080 |
Why?
|
Guanosine Triphosphate | 1 | 1990 | 316 | 0.080 |
Why?
|
Hyperparathyroidism | 4 | 1999 | 339 | 0.080 |
Why?
|
Risk Assessment | 10 | 2022 | 24123 | 0.080 |
Why?
|
Drug Therapy, Combination | 5 | 2015 | 6498 | 0.080 |
Why?
|
Practice Guidelines as Topic | 3 | 2016 | 7475 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2019 | 12293 | 0.080 |
Why?
|
Immunoglobulin A | 1 | 2013 | 979 | 0.080 |
Why?
|
Orthopedics | 2 | 2015 | 892 | 0.080 |
Why?
|
MAP Kinase Signaling System | 1 | 2016 | 1484 | 0.080 |
Why?
|
Cystatins | 1 | 2008 | 55 | 0.080 |
Why?
|
Disability Evaluation | 1 | 2016 | 1826 | 0.080 |
Why?
|
Probability | 4 | 2011 | 2475 | 0.080 |
Why?
|
Health | 1 | 2011 | 396 | 0.080 |
Why?
|
Multiple Sclerosis | 1 | 2023 | 3204 | 0.080 |
Why?
|
Geriatric Assessment | 1 | 2016 | 1405 | 0.080 |
Why?
|
Levonorgestrel | 2 | 2012 | 74 | 0.080 |
Why?
|
Body Size | 1 | 2011 | 462 | 0.070 |
Why?
|
Ethinyl Estradiol | 2 | 2012 | 114 | 0.070 |
Why?
|
Cyclic AMP | 4 | 1990 | 1456 | 0.070 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2020 | 3604 | 0.070 |
Why?
|
Health Status | 3 | 2016 | 4081 | 0.070 |
Why?
|
Nutritional Status | 4 | 2019 | 1607 | 0.070 |
Why?
|
Diet | 4 | 2020 | 8010 | 0.070 |
Why?
|
Gonadal Steroid Hormones | 2 | 2008 | 701 | 0.070 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8056 | 0.070 |
Why?
|
Calcitriol | 3 | 2012 | 297 | 0.070 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 1993 | 1153 | 0.070 |
Why?
|
Cattle | 10 | 2004 | 3847 | 0.070 |
Why?
|
Hypertension | 5 | 2021 | 8594 | 0.070 |
Why?
|
Reference Values | 5 | 2003 | 4925 | 0.070 |
Why?
|
Age Factors | 3 | 2024 | 18416 | 0.070 |
Why?
|
Fluorouracil | 1 | 2011 | 1631 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 1999 | 2532 | 0.070 |
Why?
|
Reproducibility of Results | 5 | 2011 | 20080 | 0.070 |
Why?
|
Receptors, Calcitriol | 2 | 2020 | 359 | 0.070 |
Why?
|
Mendelian Randomization Analysis | 2 | 2023 | 998 | 0.070 |
Why?
|
Kidney Function Tests | 1 | 2008 | 681 | 0.070 |
Why?
|
Diet, Carbohydrate-Restricted | 1 | 2009 | 261 | 0.070 |
Why?
|
25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2020 | 58 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2011 | 2221 | 0.060 |
Why?
|
Recovery of Function | 2 | 2008 | 2985 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2018 | 10827 | 0.060 |
Why?
|
Binding, Competitive | 1 | 2007 | 1142 | 0.060 |
Why?
|
Longitudinal Studies | 8 | 2018 | 14495 | 0.060 |
Why?
|
Depressive Disorder, Major | 1 | 2023 | 4744 | 0.060 |
Why?
|
Bone Diseases | 1 | 2009 | 419 | 0.060 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2008 | 546 | 0.060 |
Why?
|
Regression Analysis | 4 | 2002 | 6360 | 0.060 |
Why?
|
Body Weight | 4 | 2015 | 4611 | 0.060 |
Why?
|
Doxorubicin | 1 | 2011 | 2209 | 0.060 |
Why?
|
Methotrexate | 1 | 2011 | 1719 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2018 | 15289 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 2 | 2009 | 3763 | 0.060 |
Why?
|
Sex Characteristics | 1 | 2015 | 2629 | 0.060 |
Why?
|
Subcutaneous Fat | 2 | 2021 | 393 | 0.060 |
Why?
|
Progesterone Congeners | 1 | 2003 | 44 | 0.060 |
Why?
|
Peptides | 3 | 2018 | 4354 | 0.060 |
Why?
|
Energy Intake | 3 | 2012 | 2129 | 0.060 |
Why?
|
Hip | 3 | 2014 | 251 | 0.050 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2011 | 936 | 0.050 |
Why?
|
Inositol Phosphates | 3 | 2004 | 176 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3696 | 0.050 |
Why?
|
Cross-Sectional Studies | 8 | 2012 | 25942 | 0.050 |
Why?
|
Chromatography, Liquid | 1 | 2007 | 987 | 0.050 |
Why?
|
Societies, Medical | 1 | 2015 | 3905 | 0.050 |
Why?
|
Drug Administration Schedule | 3 | 1999 | 4899 | 0.050 |
Why?
|
Collagen | 2 | 2002 | 2636 | 0.050 |
Why?
|
Receptors, Calcium-Sensing | 1 | 2004 | 318 | 0.050 |
Why?
|
Hypoparathyroidism | 1 | 2004 | 136 | 0.050 |
Why?
|
Thyroglobulin | 1 | 1982 | 111 | 0.050 |
Why?
|
Prevalence | 5 | 2013 | 15687 | 0.050 |
Why?
|
Digestive System | 1 | 2003 | 244 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5325 | 0.050 |
Why?
|
Boston | 2 | 2013 | 9280 | 0.050 |
Why?
|
Veterans | 1 | 2016 | 2642 | 0.050 |
Why?
|
Treatment Outcome | 5 | 2020 | 65017 | 0.050 |
Why?
|
Cells, Cultured | 6 | 2019 | 18957 | 0.050 |
Why?
|
Intestinal Absorption | 1 | 1982 | 400 | 0.050 |
Why?
|
Dihydrotestosterone | 1 | 2001 | 195 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3839 | 0.050 |
Why?
|
Depression | 2 | 2023 | 8044 | 0.050 |
Why?
|
Drug Tolerance | 1 | 2003 | 369 | 0.050 |
Why?
|
Renin | 2 | 1982 | 635 | 0.050 |
Why?
|
Severity of Illness Index | 3 | 2010 | 15840 | 0.050 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2002 | 363 | 0.050 |
Why?
|
Triiodothyronine | 1 | 1982 | 493 | 0.050 |
Why?
|
Cytosol | 4 | 1989 | 887 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2022 | 11891 | 0.050 |
Why?
|
Administration, Oral | 3 | 1999 | 4035 | 0.040 |
Why?
|
Homeostasis | 1 | 1991 | 3306 | 0.040 |
Why?
|
Bone Morphogenetic Protein 7 | 1 | 2020 | 110 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3334 | 0.040 |
Why?
|
Delayed-Action Preparations | 2 | 1994 | 961 | 0.040 |
Why?
|
Mass Spectrometry | 1 | 2007 | 2192 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9962 | 0.040 |
Why?
|
Calcium Channel Blockers | 2 | 1995 | 694 | 0.040 |
Why?
|
Adolescent | 9 | 2014 | 87810 | 0.040 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 3150 | 0.040 |
Why?
|
Pelvic Bones | 1 | 2001 | 270 | 0.040 |
Why?
|
Multivariate Analysis | 4 | 2009 | 12159 | 0.040 |
Why?
|
Follicle Stimulating Hormone | 1 | 2001 | 725 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 15789 | 0.040 |
Why?
|
Health Policy | 1 | 2011 | 2677 | 0.040 |
Why?
|
Thyroxine | 1 | 1982 | 667 | 0.040 |
Why?
|
Heart Transplantation | 1 | 1992 | 3224 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 256 | 0.040 |
Why?
|
Receptors, Estrogen | 1 | 2006 | 2210 | 0.040 |
Why?
|
Administration, Inhalation | 1 | 2001 | 1156 | 0.040 |
Why?
|
Fruit | 1 | 2024 | 1160 | 0.040 |
Why?
|
Hormones | 1 | 2022 | 867 | 0.040 |
Why?
|
Vegetables | 1 | 2024 | 1196 | 0.040 |
Why?
|
Gastrectomy | 1 | 2003 | 679 | 0.040 |
Why?
|
Carnitine | 1 | 2019 | 252 | 0.040 |
Why?
|
Procollagen | 1 | 2018 | 188 | 0.040 |
Why?
|
Metabolic Equivalent | 1 | 2017 | 14 | 0.040 |
Why?
|
Captopril | 3 | 1984 | 265 | 0.040 |
Why?
|
Vitamin D-Binding Protein | 1 | 2018 | 131 | 0.040 |
Why?
|
Body Image | 1 | 2002 | 635 | 0.040 |
Why?
|
Quality of Life | 2 | 2016 | 13308 | 0.040 |
Why?
|
Oxidoreductases Acting on CH-CH Group Donors | 1 | 2018 | 174 | 0.040 |
Why?
|
Frail Elderly | 2 | 2016 | 752 | 0.040 |
Why?
|
Choline | 1 | 2019 | 513 | 0.040 |
Why?
|
Gene Expression Regulation | 2 | 2016 | 11903 | 0.040 |
Why?
|
Medication Adherence | 1 | 2009 | 2165 | 0.040 |
Why?
|
Peptide Fragments | 3 | 2018 | 5125 | 0.040 |
Why?
|
Parathyroidectomy | 1 | 1999 | 241 | 0.030 |
Why?
|
Cystic Fibrosis | 1 | 2006 | 1274 | 0.030 |
Why?
|
Linear Models | 3 | 2009 | 5877 | 0.030 |
Why?
|
Weight-Bearing | 2 | 2011 | 518 | 0.030 |
Why?
|
Protein-Energy Malnutrition | 2 | 1995 | 188 | 0.030 |
Why?
|
Drug Combinations | 2 | 2011 | 2025 | 0.030 |
Why?
|
Hydroxycholecalciferols | 1 | 1995 | 44 | 0.030 |
Why?
|
Alcohol Drinking | 1 | 2009 | 4013 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2515 | 0.030 |
Why?
|
Comorbidity | 2 | 2016 | 10551 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 1982 | 1523 | 0.030 |
Why?
|
Thyrotropin | 1 | 1999 | 832 | 0.030 |
Why?
|
Time Factors | 7 | 2017 | 40165 | 0.030 |
Why?
|
Hypercalcemia | 2 | 1989 | 421 | 0.030 |
Why?
|
Autoantibodies | 1 | 2004 | 2118 | 0.030 |
Why?
|
Estradiol Congeners | 1 | 1994 | 23 | 0.030 |
Why?
|
Logistic Models | 4 | 2016 | 13314 | 0.030 |
Why?
|
Liver Diseases | 1 | 2003 | 1302 | 0.030 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 1995 | 125 | 0.030 |
Why?
|
Protein Binding | 1 | 2007 | 9335 | 0.030 |
Why?
|
Norethindrone | 1 | 1994 | 56 | 0.030 |
Why?
|
Receptor Activator of Nuclear Factor-kappa B | 1 | 2014 | 77 | 0.030 |
Why?
|
Calcium-Binding Proteins | 2 | 1997 | 1067 | 0.030 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 1 | 2014 | 94 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2016 | 12531 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 36290 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 478 | 0.030 |
Why?
|
Phosphates | 2 | 1995 | 772 | 0.030 |
Why?
|
Puberty | 1 | 2017 | 498 | 0.030 |
Why?
|
Sensitivity and Specificity | 4 | 2007 | 14660 | 0.030 |
Why?
|
Macrophage Colony-Stimulating Factor | 1 | 2014 | 186 | 0.030 |
Why?
|
Waist-Hip Ratio | 1 | 2015 | 516 | 0.030 |
Why?
|
Citrates | 2 | 1991 | 135 | 0.030 |
Why?
|
ROC Curve | 2 | 2018 | 3568 | 0.030 |
Why?
|
Estrone | 1 | 1994 | 232 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2017 | 580 | 0.030 |
Why?
|
Hematocrit | 1 | 1994 | 629 | 0.030 |
Why?
|
Health Surveys | 2 | 2016 | 4063 | 0.030 |
Why?
|
Medroxyprogesterone | 1 | 1992 | 35 | 0.030 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 687 | 0.030 |
Why?
|
Calibration | 1 | 1995 | 816 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2008 | 80372 | 0.030 |
Why?
|
Vitamin A | 1 | 2015 | 613 | 0.020 |
Why?
|
Nutrition Assessment | 1 | 1995 | 727 | 0.020 |
Why?
|
Mobility Limitation | 1 | 2016 | 402 | 0.020 |
Why?
|
Cholesterol | 2 | 2013 | 2924 | 0.020 |
Why?
|
Disease Progression | 1 | 2009 | 13502 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2021 | 2061 | 0.020 |
Why?
|
Angiotensin II | 3 | 1984 | 849 | 0.020 |
Why?
|
Liver Transplantation | 1 | 2003 | 2325 | 0.020 |
Why?
|
Blood Pressure | 3 | 2021 | 8525 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2004 | 2250 | 0.020 |
Why?
|
Demography | 1 | 2016 | 1650 | 0.020 |
Why?
|
Kinetics | 3 | 1991 | 6377 | 0.020 |
Why?
|
Systems Theory | 1 | 2011 | 57 | 0.020 |
Why?
|
Growth Hormone | 1 | 1993 | 568 | 0.020 |
Why?
|
Cytokines | 2 | 2006 | 7343 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2016 | 643 | 0.020 |
Why?
|
Androgens | 1 | 1999 | 1291 | 0.020 |
Why?
|
Electric Impedance | 1 | 1995 | 755 | 0.020 |
Why?
|
Health Planning Guidelines | 1 | 2011 | 151 | 0.020 |
Why?
|
Proline | 2 | 1984 | 457 | 0.020 |
Why?
|
Knee Prosthesis | 1 | 1994 | 394 | 0.020 |
Why?
|
Citric Acid | 1 | 1991 | 123 | 0.020 |
Why?
|
Body Constitution | 1 | 2011 | 273 | 0.020 |
Why?
|
Compressive Strength | 1 | 2011 | 157 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2005 | 4925 | 0.020 |
Why?
|
Periosteum | 1 | 2011 | 138 | 0.020 |
Why?
|
Guanine Nucleotides | 2 | 1987 | 55 | 0.020 |
Why?
|
Isoproterenol | 1 | 1990 | 394 | 0.020 |
Why?
|
Animals | 15 | 2018 | 167963 | 0.020 |
Why?
|
Patient Compliance | 2 | 2012 | 2688 | 0.020 |
Why?
|
Abdominal Fat | 1 | 2012 | 223 | 0.020 |
Why?
|
Creatinine | 1 | 1995 | 1903 | 0.020 |
Why?
|
Steroid Hydroxylases | 1 | 2009 | 96 | 0.020 |
Why?
|
Case Management | 1 | 2011 | 272 | 0.020 |
Why?
|
Mexican Americans | 1 | 2010 | 165 | 0.020 |
Why?
|
Second Messenger Systems | 1 | 1990 | 202 | 0.020 |
Why?
|
New Mexico | 1 | 2009 | 83 | 0.020 |
Why?
|
Uterus | 1 | 1993 | 651 | 0.020 |
Why?
|
Postpartum Period | 1 | 1996 | 1167 | 0.020 |
Why?
|
Observer Variation | 1 | 1995 | 2601 | 0.020 |
Why?
|
Lithium | 2 | 1989 | 596 | 0.020 |
Why?
|
Diltiazem | 1 | 1989 | 131 | 0.020 |
Why?
|
Parenteral Nutrition | 1 | 1993 | 656 | 0.020 |
Why?
|
Satiation | 1 | 2009 | 83 | 0.020 |
Why?
|
Rheumatic Diseases | 1 | 1995 | 639 | 0.020 |
Why?
|
Permeability | 1 | 1990 | 719 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 1997 | 2825 | 0.020 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2003 | 2421 | 0.020 |
Why?
|
Sunlight | 1 | 2010 | 337 | 0.020 |
Why?
|
Feasibility Studies | 1 | 1999 | 5201 | 0.020 |
Why?
|
Young Adult | 2 | 2012 | 58741 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 1994 | 1817 | 0.020 |
Why?
|
Gene Expression | 2 | 2017 | 7588 | 0.020 |
Why?
|
Geography | 1 | 2010 | 661 | 0.020 |
Why?
|
Sugar Phosphates | 1 | 1987 | 44 | 0.020 |
Why?
|
Protein Kinase C | 3 | 1987 | 1199 | 0.020 |
Why?
|
Enteral Nutrition | 1 | 1993 | 785 | 0.020 |
Why?
|
Algorithms | 1 | 2007 | 13981 | 0.020 |
Why?
|
Parathyroid Diseases | 1 | 1987 | 46 | 0.020 |
Why?
|
Cystatin C | 1 | 2008 | 270 | 0.020 |
Why?
|
Postoperative Care | 1 | 1993 | 1479 | 0.020 |
Why?
|
Indians, North American | 1 | 2010 | 350 | 0.020 |
Why?
|
Fasting | 1 | 2013 | 1603 | 0.020 |
Why?
|
Phantoms, Imaging | 1 | 1995 | 2512 | 0.020 |
Why?
|
3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1986 | 48 | 0.020 |
Why?
|
Placebos | 1 | 2011 | 1668 | 0.020 |
Why?
|
Proteins | 2 | 1999 | 6029 | 0.020 |
Why?
|
Egtazic Acid | 1 | 1986 | 169 | 0.020 |
Why?
|
Feeding Behavior | 1 | 2018 | 3185 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2864 | 0.020 |
Why?
|
Aminoquinolines | 1 | 1986 | 108 | 0.020 |
Why?
|
Odds Ratio | 2 | 2008 | 9716 | 0.020 |
Why?
|
Social Support | 1 | 2016 | 2145 | 0.020 |
Why?
|
Exocytosis | 1 | 1987 | 319 | 0.020 |
Why?
|
Renal Dialysis | 1 | 1995 | 1801 | 0.020 |
Why?
|
Lung Diseases | 1 | 1995 | 1915 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 1986 | 818 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2012 | 2659 | 0.010 |
Why?
|
Kidney | 1 | 2020 | 7064 | 0.010 |
Why?
|
Femoral Fractures | 1 | 2008 | 375 | 0.010 |
Why?
|
Diabetes Mellitus | 2 | 2009 | 5889 | 0.010 |
Why?
|
Genotype | 1 | 2018 | 12960 | 0.010 |
Why?
|
Physical Fitness | 1 | 2008 | 732 | 0.010 |
Why?
|
Seasons | 1 | 2010 | 1522 | 0.010 |
Why?
|
Hand | 1 | 2009 | 903 | 0.010 |
Why?
|
Magnesium | 1 | 1987 | 810 | 0.010 |
Why?
|
Addison Disease | 1 | 2004 | 48 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 17790 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2007 | 2262 | 0.010 |
Why?
|
Calcimycin | 1 | 1983 | 213 | 0.010 |
Why?
|
Walking | 1 | 2011 | 1189 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2004 | 814 | 0.010 |
Why?
|
Adrenal Glands | 2 | 2001 | 554 | 0.010 |
Why?
|
Asthma | 1 | 2001 | 6172 | 0.010 |
Why?
|
Tissue Extracts | 1 | 1982 | 140 | 0.010 |
Why?
|
Graves Disease | 1 | 2004 | 239 | 0.010 |
Why?
|
Ascorbic Acid | 1 | 2005 | 655 | 0.010 |
Why?
|
Anthropometry | 1 | 2007 | 1348 | 0.010 |
Why?
|
Imidazoles | 1 | 2007 | 1180 | 0.010 |
Why?
|
Motor Activity | 1 | 2011 | 2687 | 0.010 |
Why?
|
Prostaglandins E | 1 | 1981 | 169 | 0.010 |
Why?
|
Desoxycorticosterone | 1 | 1980 | 46 | 0.010 |
Why?
|
Counseling | 1 | 2009 | 1548 | 0.010 |
Why?
|
Models, Statistical | 1 | 1995 | 5075 | 0.010 |
Why?
|
Metabolic Clearance Rate | 3 | 1988 | 361 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11152 | 0.010 |
Why?
|
Ultrasonography | 1 | 1993 | 5961 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1983 | 2558 | 0.010 |
Why?
|
Hospitalization | 2 | 2011 | 10790 | 0.010 |
Why?
|
Attitude to Health | 1 | 2009 | 2029 | 0.010 |
Why?
|
Aldosterone | 2 | 1984 | 868 | 0.010 |
Why?
|
Forecasting | 1 | 2009 | 2932 | 0.010 |
Why?
|
Age Distribution | 1 | 2005 | 2893 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2008 | 1869 | 0.010 |
Why?
|
Antirheumatic Agents | 1 | 2009 | 1374 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2004 | 1246 | 0.010 |
Why?
|
Up-Regulation | 1 | 2008 | 4122 | 0.010 |
Why?
|
Cell Line | 2 | 2004 | 15620 | 0.010 |
Why?
|
Blood Glucose | 1 | 2013 | 6381 | 0.010 |
Why?
|
Insulin | 1 | 2013 | 6597 | 0.010 |
Why?
|
Nasal Cavity | 1 | 2000 | 304 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 1986 | 1913 | 0.010 |
Why?
|
Stem Cells | 1 | 2011 | 3523 | 0.010 |
Why?
|
Immune Sera | 1 | 1997 | 613 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2008 | 2919 | 0.010 |
Why?
|
Ovary | 1 | 2001 | 958 | 0.010 |
Why?
|
Inflammation | 1 | 2017 | 10756 | 0.010 |
Why?
|
Histocytochemistry | 1 | 1997 | 700 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1997 | 1055 | 0.010 |
Why?
|
Blotting, Western | 1 | 2004 | 5039 | 0.010 |
Why?
|
Quality Improvement | 1 | 2011 | 3836 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1997 | 1543 | 0.010 |
Why?
|
Transfection | 1 | 2004 | 5781 | 0.010 |
Why?
|
Bromides | 1 | 1995 | 22 | 0.010 |
Why?
|
Deuterium Oxide | 1 | 1995 | 34 | 0.010 |
Why?
|
Cell Division | 1 | 1983 | 4463 | 0.010 |
Why?
|
Sodium Compounds | 1 | 1995 | 35 | 0.010 |
Why?
|
Thyroid Gland | 1 | 1982 | 1168 | 0.010 |
Why?
|
Antibody Specificity | 1 | 1997 | 1060 | 0.010 |
Why?
|
Body Water | 1 | 1995 | 341 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2000 | 3465 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2000 | 1548 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1997 | 1900 | 0.010 |
Why?
|
Cell Count | 1 | 1997 | 1835 | 0.010 |
Why?
|
Fats | 1 | 1993 | 99 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1995 | 1628 | 0.010 |
Why?
|
Carbohydrate Metabolism | 1 | 1993 | 262 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 1999 | 1392 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2008 | 10446 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2000 | 6238 | 0.010 |
Why?
|
Apoptosis | 1 | 2008 | 9501 | 0.010 |
Why?
|
Enzyme Activation | 2 | 1987 | 3602 | 0.010 |
Why?
|
Risk | 1 | 2003 | 9631 | 0.010 |
Why?
|
Fura-2 | 1 | 1989 | 107 | 0.010 |
Why?
|
Calcium Gluconate | 1 | 1988 | 22 | 0.010 |
Why?
|
Child | 1 | 2017 | 79806 | 0.010 |
Why?
|
Lithium Carbonate | 1 | 1989 | 179 | 0.000 |
Why?
|
Mice, Inbred BALB C | 1 | 1997 | 6216 | 0.000 |
Why?
|
Benzofurans | 1 | 1989 | 142 | 0.000 |
Why?
|
Chronic Disease | 1 | 2003 | 9287 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1997 | 6068 | 0.000 |
Why?
|
Edetic Acid | 1 | 1988 | 282 | 0.000 |
Why?
|
Electrolytes | 1 | 1988 | 274 | 0.000 |
Why?
|
Stimulation, Chemical | 1 | 1987 | 306 | 0.000 |
Why?
|
Decision Support Techniques | 1 | 1997 | 2001 | 0.000 |
Why?
|
Fluorides | 1 | 1987 | 134 | 0.000 |
Why?
|
Type C Phospholipases | 1 | 1987 | 287 | 0.000 |
Why?
|
Base Sequence | 1 | 1997 | 12446 | 0.000 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 1994 | 1489 | 0.000 |
Why?
|
Cell Membrane Permeability | 1 | 1987 | 575 | 0.000 |
Why?
|
Extracellular Space | 1 | 1987 | 564 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1997 | 17624 | 0.000 |
Why?
|
Prognosis | 1 | 2005 | 29658 | 0.000 |
Why?
|
p-Aminohippuric Acid | 1 | 1984 | 36 | 0.000 |
Why?
|
Nucleotides | 1 | 1986 | 450 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1997 | 11071 | 0.000 |
Why?
|
Infusions, Intravenous | 1 | 1988 | 2234 | 0.000 |
Why?
|
Renal Circulation | 1 | 1984 | 291 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1997 | 12766 | 0.000 |
Why?
|
Electric Stimulation | 1 | 1987 | 1735 | 0.000 |
Why?
|
Energy Metabolism | 1 | 1993 | 2869 | 0.000 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1987 | 2502 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1993 | 8552 | 0.000 |
Why?
|
Postoperative Period | 1 | 1986 | 1818 | 0.000 |
Why?
|
Transplantation, Autologous | 1 | 1986 | 2116 | 0.000 |
Why?
|
Norepinephrine | 1 | 1984 | 900 | 0.000 |
Why?
|
Models, Biological | 1 | 1997 | 9467 | 0.000 |
Why?
|
Indomethacin | 1 | 1981 | 326 | 0.000 |
Why?
|
Prostaglandins | 1 | 1981 | 398 | 0.000 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 1981 | 361 | 0.000 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 1981 | 364 | 0.000 |
Why?
|
Plasma | 1 | 1980 | 584 | 0.000 |
Why?
|
Posture | 1 | 1980 | 953 | 0.000 |
Why?
|
Acute Disease | 1 | 1986 | 7269 | 0.000 |
Why?
|
Mice | 1 | 1997 | 81208 | 0.000 |
Why?
|
Aspirin | 1 | 1981 | 3364 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1986 | 26181 | 0.000 |
Why?
|